Eureka Biotechnology Co., Limited

Eureka Biotechnology Co., Limited is a trailblazer in the field of cell and gene therapy, providing a lentiviral vector stable producer cell line system and GMP closed automated equipment for ATMP. The company's integration of automation technology, artificial intelligence, and diverse disciplines with biotechnology has successfully addressed crucial technological challenges in gene therapy, cell therapy, life science, and pharmaceutical R&D. Emphasizing cross-disciplinary collaboration and technological innovation, Eurekabio has consistently pushed the boundaries of therapy, bringing forth advanced cellular drug production solutions and the EuLV lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are set to play a pivotal role in the global commercialization of CGT drugs. Since its establishment in 2014 in China, the company has garnered significant attention from investors, with the latest CNY300.00M Series B investment led by Eight Roads Ventures, Fortune Venture Capital, Asia Business Corporation Group, CWB Capital, Tasly Capital, Guangzhou Yuexiu Industrial Investment Fund, and Guangdong Technology Financial Group on 21 February 2024. As Eurekabio strives to usher in a new era of advanced and accessible therapies, it positions itself as an influential player in the biotechnology and healthcare industries.